Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports.

The oncologist - 1 Dec 2025

He Xin, Xie Sidong, Jia Changchang, Wu Xiangyuan, Chen Zhanhong, Wang Tiantian

Abstract excerpt

BACKGROUND: Biliary tract cancer (BTC), as a relatively rare tumor, carries a poor prognosis. While immunotherapy combined with chemotherapy can extend survival, response rates remain low. Targeted therapies tailored to specific genetic mutations may improve outcomes when paired with immune checkpoint inhibitors. This report examines 2 cases of advanced BTC with distinct genetic alterations, treated with targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms
Share to BTC gene
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 41396681
DOI: 10.1093/oncolo/oyaf374
PMCID: PMC12715304

Genes

BTC
BRAF
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports.PMID 41396681Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

Translating cancer genomics for precision oncology in biliary tract cancers.Semantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Mutational spectrum and precision oncology for biliary tract carcinoma.Semantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Precision Oncology in Cholangiocarcinoma: Current Standards and Future DirectionsSemantic proximity Read ↗

Molecular genetics and targeted therapeutics in biliary tract carcinoma.Semantic proximity Read ↗

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune SignaturesSemantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.Semantic proximity Read ↗

Genomics driven precision oncology in advanced biliary tract cancer improves survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.